Gainers

• Cue Biopharma (NASDAQ:CUE) stock rose 90.1% to $28.02 during Friday's pre-market session. The company's market cap stands at $47.9 million.
• Esperion Therapeutics (NASDAQ:ESPR) stock increased by 57.0% to $3.14. The company's market cap stands at $514.8 million.
• Akanda (NASDAQ:AKAN) shares rose 30.26% to $63.78. The company's market cap stands at $26.1 million.
• Psyence Biomedical (NASDAQ:PBM) stock moved upwards by 19.11% to $7.85. The market value of their outstanding shares is at $6.7 million.
• iSpecimen (NASDAQ:ISPC) stock increased by 17.2% to $6.13. The company's market cap stands at $3.8 million.
• Cerus (NASDAQ:CERS) stock rose 15.02% to $2.33. The market value of their outstanding shares is at $406.7 million. As per the news, the Q1 earnings report came out yesterday.

Losers

• Akari Therapeutics (NASDAQ:AKTX) shares decreased by 25.9% to $4.0 during Friday's pre-market session. The market value of their outstanding shares is at $192.9 million.
• Senseonics Holdings (NASDAQ:SENS) shares fell 22.24% to $5.14. The company's market cap stands at $276.3 million.
• Rein Therapeutics (NASDAQ:RNTX) shares fell 21.78% to $1.06. The company's market cap stands at $37.9 million.
• Summit Therapeutics (NASDAQ:SMMT) stock decreased by 20.55% to $17.05. The company's market cap stands at $16.6 billion. As per the press release, Q1 earnings came out yesterday.
• Sotera Health (NASDAQ:SHC) stock decreased by 10.75% to $13.89. The market value of their outstanding shares is at $4.4 billion.
• Crescent Biopharma (NASDAQ:CBIO) stock decreased by 8.68% to $20.43. The company's market cap stands at $681.4 million. As per the press release, Q1 earnings came out 2 days ago. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.